Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Mar 16

PMID 30873378

Citations 12

Authors

Robert Frank Cornell

Samuel Z Goldhaber

Brian G Engelhardt

Javid Moslehi

Madan Jagasia

Daryl Patton

Shelton Harrell

Robert Hall

Houston Wyatt

Greg Piazza

Affiliations

Soon will be listed here.

Abstract

Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE and for risk reduction of recurrent VTE following initial therapy. In this phase IV single-arm study (NCT02958969), we aim to prospectively evaluate the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The primary efficacy objective of this trial is to determine the rate of symptomatic VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), over 6 months. The primary safety objective is to determine the rate of major bleeding in MM patients receiving apixaban prophylaxis. If proven safe and effective, apixaban will emerge as a promising option for oral VTE prophylaxis in MM patients.

Citing Articles

Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.

Charalampous C, Shah D, Kumar S, Chakraborty R Ann Hematol. 2024; 103(10):3881-3888.

PMID: 38630132 DOI: 10.1007/s00277-024-05733-9.

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Geraldes C, Roque A, Sarmento-Ribeiro A, Neves M, Ionita A, Gerivaz R Front Oncol. 2024; 14:1282300.

PMID: 38585008 PMC: 10995327. DOI: 10.3389/fonc.2024.1282300.

Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.

Covut F, Sanfilippo K Hematology Am Soc Hematol Educ Program. 2022; 2022(1):363-367.

PMID: 36485142 PMC: 9820182. DOI: 10.1182/hematology.2022000414.

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.

Fu W, Wang Y, Zhao H, Niu T, Fang B, Liao A BMC Cancer. 2022; 22(1):722.

PMID: 35778685 PMC: 9250185. DOI: 10.1186/s12885-022-09802-y.

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

Kahale L, Matar C, Tsolakian I, Hakoum M, Yosuico V, Terrenato I Cochrane Database Syst Rev. 2021; 9:CD014739.

PMID: 34582035 PMC: 8477647. DOI: 10.1002/14651858.CD014739.

References

Osman K, Comenzo R, Rajkumar S . Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001; 344(25):1951-2. DOI: 10.1056/NEJM200106213442516. View

Schulman S, Kearon C . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-4. DOI: 10.1111/j.1538-7836.2005.01204.x. View

Martel N, Lee J, Wells P . Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106(8):2710-5. DOI: 10.1182/blood-2005-04-1546. View

Lassen M, Davidson B, Gallus A, Pineo G, Ansell J, Deitchman D . The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5(12):2368-75. DOI: 10.1111/j.1538-7836.2007.02764.x. View

Hicks L, Haynes A, Reece D, Walker I, Herst J, Meyer R . A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev. 2008; 34(5):442-52. DOI: 10.1016/j.ctrv.2008.02.003. View

Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Portman R . Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361(6):594-604. DOI: 10.1056/NEJMoa0810773. View

Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2009; 11(1):29-37. PMC: 3042271. DOI: 10.1016/S1470-2045(09)70284-0. View

Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Hornick P . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807-15. DOI: 10.1016/S0140-6736(09)62125-5. View

Fanikos J, Stevens L, Labreche M, Piazza G, Catapane E, Novack L . Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med. 2010; 123(6):536-41. DOI: 10.1016/j.amjmed.2009.11.017. View

10.

Zonder J, Crowley J, Hussein M, Bolejack V, Moore Sr D, Whittenberger B . Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010; 116(26):5838-41. PMC: 3031379. DOI: 10.1182/blood-2010-08-303487. View

11.

Lassen M, Gallus A, Raskob G, Pineo G, Chen D, Ramirez L . Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363(26):2487-98. DOI: 10.1056/NEJMoa1006885. View

12.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F . Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011; 29(8):986-93. DOI: 10.1200/JCO.2010.31.6844. View

13.

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

14.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A . Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2011; 119(4):933-9. DOI: 10.1182/blood-2011-03-344333. View

15.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

16.

Agrawal R, Jain P, Dikshit S . Apixaban: a new player in the anticoagulant class. Curr Drug Targets. 2012; 13(6):863-75. DOI: 10.2174/138945012800564059. View

17.

Raskob G, Gallus A, Pineo G, Chen D, Ramirez L, Wright R . Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012; 94(2):257-64. DOI: 10.1302/0301-620X.94B2.27850. View

18.

Levine M, Gu C, Liebman H, Escalante C, Solymoss S, Deitchman D . A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012; 10(5):807-14. DOI: 10.1111/j.1538-7836.2012.04693.x. View

19.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-91. DOI: 10.1056/NEJMoa1114138. View

20.

Leebeek F, Kruip M, Sonneveld P . Risk and management of thrombosis in multiple myeloma. Thromb Res. 2012; 129 Suppl 1:S88-92. DOI: 10.1016/S0049-3848(12)70024-5. View